Warning: Missing argument 1 for get_pagelink_by_slug(), called in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/header.php on line 111 and defined in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/admin/functions-theme-basic.php on line 98

期刊《日中医学》

特辑:与日俱增的中日两国呼吸道疾病的研究与临床领域的新资讯

前言 呼吸道疾病的多元化

岛根大学内科学教研室呼吸道与临床肿瘤学 教授
矶部 威

中国慢性阻塞性肺疾病研究与临床的最前沿

中日友好医院呼吸与危重症医学科 医师
黄 可

Cutting-Edge of Current Research and Clinical Activity for COPD in China
 

【Abstract】
Chronic obstructive pulmonary disease(COPD)leads to high disease burden in China, but needs further prevention and management. In recent years, Chinese experts has gained important progress in research and clinical work of COPD, including disease burden survey, risk factors analysis, phenotype research and drug treatment. This review summarized these progresses in recent years.

【Key words】
Chronic obstructive pulmonary disease, disease burden, phenotype, treatment

中国肺动脉高压研究与临床的最前沿

西安交通大学第二附属医院 副研究员
王 蕾

Cutting-Edge of Current Research and Clinical Activity for Pulmonary Hypertension in China
 

【Abstract】
In the past 10 years, pulmonary hypertension research in China has made great progresse. With the in-depth research on its pathogenesis and the development of guidelines, the treatment behavior of Chinese clinicians has been standardized, and the clinical treatment of pulmonary hypertension in China has been improved, which thereby significantly improving the prognosis of Chinese pulmonary hypertension patients, and survival rate almost reaches the level of developed countries. This article will summarize the current situation of research and clinical treatment for pulmonary hypertension in China.

【Key words】
pulmonary hypertension, treatment, research

日本慢性阻塞性肺疾病研究与临床的最前沿

横滨市立大学研究生院医学研究科呼吸器病学 主任教授
金子 猛

Cutting-Edge of Current Research and Clinical Activity for COPD in Japan
 

【Abstract】
We introduce three relevant topics from our studies in the diagnosis and treatment of COPD. First, heme oxygenase-1, an inducible protein activated in systemic infl ammatory conditions by oxidant stress, shows efficacy as a serum biomarker for predicting the risk of developing COPD. Second, our systematic review of the clinical trials comparing LAMA/LABA and ICS/LABA to prevent COPD exacerbation is essential for understanding the positioning of ICS. Last, clarithromycin (CAM)suppression of the IL-13-induced MUC5AC expression pathway demonstrates the mechanism by which CAM reduces airway hypersecretion in COPD patients.

【Key words】
heme oxygenase-1, LAMA/LABA, ICS/LABA, MAC5AC, macrolide antibiotics, clarithromycin

日本肺动脉高压研究与临床的最前沿

顺天堂大学研究生院医学研究科呼吸内科学
长冈铁太郎※1、栗山祥子、堤建男
※1.副教授(通讯作者)

Cutting-Edge of Current Research and Clinical Activity for Pulmonary Hypertension in Japan
 

【Abstract】
Recent advances on the treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are remarkable. Results of translational researches from Japan indicate the novel mechanism of disease progression. High dose epoprostenol and balloon pulmonary angioplasty established in Japan are becoming the new standard therapy in global. Previous basic and clinical researches from Japan contribute to the development of therapeutic strategy for those pulmonary hypertension.

【Key words】
pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension with chronic lung disease, epoprostenol, balloon pulmonary angioplasty

 

纽 带 
       
       

通过国际合作与中国结缘
东京女子医科大学国际环境/热带医学教研室 教授/教研室主任
杉下智彦

笹川生 in China 
      
      

抗击新冠病毒 ~ 援鄂归来仍少年
中国医科大学附属第一医院胸外科 副教授、副主任医师
李文雅

后 记 宣传委员会委员  高桥和久
期刊《日中医学》一般投稿征稿通知